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Cervical cancer (CxCa) remains the fourth leading cause of cancer related deaths among women
worldwide. Cervical cancer is mainly (~ 99.7%) derived from high risk Human papillomavirus (HR HPV).
HPV E6/E7 are the two main oncoproteins that interfere with p53 and pRb (retinoblastoma) cell cycle
regulatory proteins and hinder their efficacy of controlling cell growth. Additionally, PI3K-Akt is a cell
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urgent need to develop newer treatment modalities. Ormeloxifene (ORM) is a non-hormonal, antiestrogen, oral contraceptive for human use. Growing evidences also suggest that ormeloxifene has anticancerous properties in a variety of cancers. Developing nanoformulation of drugs has received much
attention lately as nanoparticles have site specific targeted drug delivery. Nanoparticles have a specific
size range that makes them capable of being entrapped and accumulated at the tumor site due to its
leaky vasculature. As a result of it, drug is released from the particle core at a sustained rate; therefore,
nanoparticulates offer enhanced bioavailability and better therapeutic efficacy. Considering these
benefits, we engineered ormeloxifene loaded PLGA based novel nanoformulation (PLGA-ORM). In this
work we validated anti-cancer properties of free ORM and its PLGA based nanoformulation. Our set of
data showed that ormeloxifene significantly decreased the cellular proliferation and clonogenic potential
of cervical cancer cells. Ormeloxifene also reduced the cellular motility and induced the apoptosis via
targeting PI3K-Akt signaling in these cells. Furthermore, ormeloxifene modulated the HPV induced
oncogenesis in Caski cells. Ormeloxifene also showed additive inhibitory effects on cellular proliferation
and growth when used with radiation. Moreover, our novel PLGA-ORM had a particle size range of 100 –
280 nm and also exhibited excellent encapsulation of ormeloxifene in to PLGA core. PLGA-ORM was
labeled with Coumarin 6 (green fluorescent) dye for its uptake studies, where PLGA-ORM internalized in
cervical cancer cells in dose, time and energy dependent manner via endocytosis pathway. PLGA-ORM
showed improved anti-proliferative/growth properties than free ormeloxifene in cervical cancer cells.
When utilized in animals (an orthotopic mouse model) both ormeloxifene and PLGA-ORM showed great
anti-tumorous properties, however PLGA-ORM had improved inhibitory effects on tumor growth than free
ormeloxifene. To conclude, ormeloxifene and its nanoformulation have the potential to be a novel
treatment modality for cervical cancer which can reduce the overall disease burden and improve patients’
life expectancy.
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ABSTRACT
Cervical cancer (CxCa) remains the fourth leading cause of cancer related deaths
among women worldwide. Cervical cancer is mainly (~ 99.7%) derived from high risk
Human papillomavirus (HR HPV). HPV E6/E7 are the two main oncoproteins that
interfere with p53 and pRb (retinoblastoma) cell cycle regulatory proteins and hinder
their efficacy of controlling cell growth. Additionally, PI3K-Akt is a cell survival
pathway that is aberrantly expressed in cervical cancer cells. This pathway has a
profound role in inhibiting mitochondrial intrinsic apoptotic signaling pathway.
Advanced stage cervical cancer is difficult to treat and patients diagnosed with metastatic
disease have a poor survival rate. Therefore, there is an urgent need to develop newer
treatment modalities. Ormeloxifene (ORM) is a non-hormonal, anti-estrogen, oral
contraceptive for human use. Growing evidences also suggest that ormeloxifene has anticancerous properties in a variety of cancers. Developing nanoformulation of drugs has
received much attention lately as nanoparticles have site specific targeted drug delivery.
Nanoparticles have a specific size range that makes them capable of being entrapped and
accumulated at the tumor site due to its leaky vasculature. As a result of it, drug is
released from the particle core at a sustained rate; therefore, nanoparticulates offer
enhanced bioavailability and better therapeutic efficacy. Considering these benefits, we
engineered ormeloxifene loaded PLGA based novel nanoformulation (PLGA-ORM). In
this work we validated anti-cancer properties of free ORM and its PLGA based
nanoformulation. Our set of data showed that ormeloxifene significantly decreased the
cellular proliferation and clonogenic potential of cervical cancer cells. Ormeloxifene also
reduced the cellular motility and induced the apoptosis via targeting PI3K-Akt signaling
in these cells. Furthermore, ormeloxifene modulated the HPV induced oncogenesis in
Caski cells. Ormeloxifene also showed additive inhibitory effects on cellular proliferation
and growth when used with radiation. Moreover, our novel PLGA-ORM had a particle
size range of 100 – 280 nm and also exhibited excellent encapsulation of ormeloxifene in
to PLGA core. PLGA-ORM was labeled with Coumarin 6 (green fluorescent) dye for its
uptake studies, where PLGA-ORM internalized in cervical cancer cells in dose, time and
energy dependent manner via endocytosis pathway. PLGA-ORM showed improved antiproliferative/growth properties than free ormeloxifene in cervical cancer cells. When
utilized in animals (an orthotopic mouse model) both ormeloxifene and PLGA-ORM
showed great anti-tumorous properties, however PLGA-ORM had improved inhibitory
effects on tumor growth than free ormeloxifene. To conclude, ormeloxifene and its
nanoformulation have the potential to be a novel treatment modality for cervical cancer
which can reduce the overall disease burden and improve patients’ life expectancy.
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CHAPTER 1.

INTRODUCTION*

Statement of the Problem
Cervical Cancer
Cervical cancer stands at the fourth rank among most common and deadly
malignancies in women globally. In the year of 2012, cervical cancer accounted for
528,000 new cases and 266,000 death incidences around the world. Incidence rates
remain higher in less developed countries (15.7%) than more developed countries (9.9%)
mainly in Eastern (42.7%), Middle (30.6%) and South Africa (31.5%) [1]. In developing
countries this is the major cause in women who are at reproductive age and the reason
being is less awareness and availability of screening modalities [2-4].
Cervical Cancer and Human Papillomavirus
Cervical cancer is primarily associated with the high risk Human Papillomavirus
(HPV) infection [5-9]. HPV’s are circular, double stranded DNA viruses consisting of
about 8000 base pairs (Figure 1-1) [10-14] and are the most common type of sexually
transmitted virus infection [15-17]. Upon the classification, there are more than 100 well
known human papillomaviruses which are further divided in to two categories – High
Risk and Low Risk (Figure 1-2) [18]. Persistent infection of any of these 13 High risk
HPV’s (HVP 16, 18, 31, 33, 35, 39,45, 51, 52, 56, 59 and 66) can result in the
progression of cervical cancer [19, 20] while Low Risk HPVs such as 2, 4, 5, 10 and 15
are known to cause warts [21-23]. HPV 16 and 18 are the most shared type of HPVs and
account for about 70 % of invasive cervical cancer cases [24]. Like other cancers,
cervical cancer also has various changes at genetic level, loss of 11q and gain of 3q are a
common characteristic change in HPV positive cells [25, 26]. HPV infection can either
be latent or active [27], if the virus completes its life cycle then it is a latent infection
[28]. When a virus completes the life cycle, huge production of viral progeny is desired
which is carried out by the HPV replication protein E1 and mainly E2 [29]. E2 is the
major player in HPV life cycle which controls the expression of other viral genes [30].
When the virus starts integrating in to host cell genome, this event deregulates the E2
replication protein, this deregulation of E2 eventually leads to the increased expression of
E6 and E7 as they are repressed by E2 [30]. During the life cycle, E6 and E7 are
expressed at the lower epithelial layer of cells where these two proteins facilitate cells as
they move from G1 cell cycle phase to S phase which is the synthesis phase, thus,
expression of HPV E6 and E7 results in elevated rate of cell proliferation [31-33]. Capsid
----------------------------* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 1-1. Diagram shows the structure of HPV.
Modified with permission. Yugawa, T. and T. Kiyono, Molecular mechanisms of cervical
carcinogenesis by high‐risk human papillomaviruses: novel functions of E6 and E7
oncoproteins. Reviews in medical virology, 2009. 19(2): p. 97-113.

Figure 1-2.

Diagram shows the general classification of HPVs.

2

proteins L1 and L2 are expressed at the upper epithelial layer cells along with E4 to
gather and provide structure to the progenies [28]. Malignant cervical cancer cells
specifically express two viral oncoproteins HPV E6 and E7 [34]. HPV E6 and E7 are
known to cause genomic alterations resulting in gain or loss of function of genes in
various cancers including cervical cancer [25, 26]. E6 and E7 disturb the functions of p53
(protein 53) and Rb (Retinoblastoma protein), two tumor suppressor proteins. Both the
proteins regulate cell cycle progression and excessive cell proliferation. The E6 binds to
p53 and degrades it by proteosomal degradation [35, 36]. Whereas the E7 oncoprotein
binds to Rb and degrades it which leads to the induction of cell growth and gene
promoting DNA synthesis [37, 38]. Rb specifically (pRb) binds to the E2F which is
transcription factor, and prevents E2F from interacting with other cyclins and cyclin
dependent kinases, thus, inhibiting proliferation. But upon the binding of E7, pRB cannot
perform this preventive action on E2F which allows E2F to interact with other cyclins
and thus, promotes cell proliferation and cell cycle progression (Figure 1-3) [39-42].
PTPN 13 is a nonreceptor phosphatase that also gets degraded by HPV E6 upon its
binding [43].
Other Risk Factors
Though HPV is the most common factor of cervical cancer yet alone it is not
enough to develop cervical cancer and requires other risk factors such as smoking,
multiple sexual partners, and first intercourse at young age, use of oral contraceptives and
low socioeconomic status [44-47]. Some case control studies show an establishment
between the use of oral contraception and development of cervical cancer but the studies
are of poor quality and data is inconsistent and insignificant as the confidence interval
values (CIs) were wide [48-50]. Also, there is a good number of studies which report that
association between oral contraceptive and HPV infection/ cervical cancer is just due to
the reason that women already being on one type of birth control strategy are very likely
not to use other protection system, thus are more prone to get infection via sexual
contacts [51-54]. Among females, cigarette smoking has two times higher risk of having
cervical cancer than those who do not smoke [16], even the secondary exposure to
cigarette smoke has been associated with the incidences of cervical cancer [55, 56]. A
well-known cigarette smoke carcinogen, BaP (Banzo[a]pyrene increases the expression
levels of HPV oncoproteins E6 and E7 in cervical cancer cells [57]. There are reports that
suggest that cigarette smoke residuals are found in the mucus sample of women who
smoke [58-60]. Epidemiology of cervical cancer suggests that having multiple sexual
partners and young age at first sexual intercourse, increases the risk for HPV infection
and development of cervical cancer among women [61, 62]. One other risk factor that
also contributes toward developing cervical cancer, is elevated hormones especially
estrogen and progesterone during the pregnancies which effects the HPV regulation in the
system [63]. There is a link between estrogen receptor α and cervical cancer
tumorigenesis. Estrogen receptor α promotes tumor development in HPV transgenic
cervical cancer mice model where as mice that were given no estrogen receptor showed
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Figure 1-3. A schematic of cell cycle progression.
Modified with permission. Dehay, C. and H. Kennedy, Cell-cycle control and cortical
development. Nature Reviews Neuroscience, 2007. 8(6): p. 438-450.
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no symptoms of developing tumors. Therefore, molecules that can target estrogen
receptor, hold great promises to become anti-cervical cancer agents [64].
Other Oncogenic Signaling in Cervical Cancer
It is known that HPV infection changes or modulates different signaling pathways
which eventually leads to the induction of cervical cancer [65]. HPV signaling needs few
other different pathways in order to promote cell survival and proliferation namely Ras,
Notch receptor, Growth factor receptor and PI3KCA [66-69]. PI3K-Akt signaling gets
modulated and activated by HPV E6 and E7 [70, 71]. PI3K-Akt is a cell survival pathway
which is responsible for many cellular functions such as cell proliferation, cell survival
and cell cycle progression in variety of cancers [72-74]. PI3K-Akt is one of the most
aberrantly expressed pathways in cervical cancer cells [75-78]. Akt becomes
phosphorylated at serine and threonine residuals by the overexpression of PI3K [79] and
thus, gets activated for the further initiation of apoptosis cascade [80]. Human cervical
cancer tissue samples express the increased levels of pAkt [81], therefore, PI3K-Akt
signaling pathway has gained much attention for the therapeutic aspects in cervical
cancer [82].
Current Available Treatments and Their Limitations
In many developed countries Pap Smear Screening (Pap test) is available to detect
the pre-cancerous changes at the cervix which has greatly reduced the incidences
(occurrence) of cervical cancer as the pre-cancerous lesions can be detected and followed
up by treatments, [54] but it is also reported that Pap screening results in almost about
20% of false negative results [83]. HPV testing is also available for the detection of high
risk HPVs alone or in the combination with Pap test [84]. Being a viral disease, there are
many vaccines generated and available too for prevention purposes of cervical cancer
[85]. Gardasil and Cervarix are two approved vaccines that are in human use and provide
100% protection against HPV 16 and 18 which has been reported to last up to 8-9 years
[86-88]. Current treatment modalities available for the management of cervical cancer are
disease stage dependent; early stage patients are mainly advised surgery or radiotherapy
[89, 90] whereas late stages of cervical cancer are tackled by radiation along with
cisplatin based chemotherapy [91].
Although cervical cancer is highly preventable, yet the mortality rate remains high
and reasons are the limitations and drawbacks of current prevention and treatment
modalities. The available vaccines for preventing the disease have age limitation. They
are suggested to use between the ages of 13 to 26 but vaccination can be started as early
as at age 11 [92]. The other treatment methods such as surgery, radiation and
chemotherapy have their own adverse effects. Patients often suffer from weakness,
fatigue, weight loss, appetite loss and infertility. Despite of having many current
available treatment choices, 100% success rate is not guaranteed and usual recurrence
time is 2 years [93-95].
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Repurposing of Drugs
According to an estimate it takes almost 15-20 years and about $800 million USD
of cost to get a new drug entity to the market [96, 97] and that too comes with constraint
of Food and Drug Administration (FDA) as FDA only approves less than 30 new
compounds every year [97, 98]. All these obstacles make it difficult to discover new
drugs for cancer management [99]. In order to overcome this issue one proposed
mechanism is to reuse the drugs that are already in market for other uses [100]. This
newer approach is called “drug repositioning” or “drug repurposing” or “drug reprofiling” or “therapeutic switching” [101]. There are various molecules that have been
repurposed for cancer treatment. Some of the illustrations given here are recent studies
with metformin on various cancer treatments [102-104] which traditionally is an antidiabetic molecule [105]. Aspirin which is a very well know analgesic has been
established as a potent anti-cancer molecule for metastatic lung cancer [106], as well as
brain, esophageal, pancreatic and gastrointestinal [107], and it is also reported that long
term (up to 5 years) daily consumption of aspirin can reduce the risk of developing
colorectal cancer [108]. Another very well described example of drug-repositioning is
rapamycin which is a known inhibitor of mTOR pathway which is highly expressed in
various cancers [109]. Therefore, rapamycin has been studied for its anti-cancer
properties and it shows brilliant anti-tumorous activities for myeloid leukemia [110] and
myelogenous leukemia [111].
Ormeloxifene
Ormeloxifene (Centchroman), C30H35O3N.HCl, (Figure 1-4) [112] is a nonsteroidal, non-hormonal anti-estrogen oral contraceptive for human use that is taken once
per week and was first synthesized by Central Drug Research Institute, India [113].
Ormeloxifene is a SERM (Selective Estrogen Receptor Modulator) which inhibits
estrogen receptors (ER) in uterus, cervix, ovary and breast while promoting these
receptors in other organs such as bones [114, 115]. Ormeloxifene is a crystalline
molecule, white in color and has a molecular weight of 493.5Da. It is insoluble in water
but soluble in ethanol, methanol, acetone and chloroform (organic solvents) [114, 116].
Ormeloxifene is stable at room temperature and 4°C with maintaining its biological
activities [117]. Ormeloxifene showed excellent pharmacokinetic and pharmacodynamics
properties with low binding affinity toward human plasma proteins and no affinity toward
steroids present in the body [118-123]. Ormeloxifene is generally metabolized by liver
but if high amounts of the drug are provided, traces can be found in spleen, lungs and
uterus [124, 125]. In animals (adult female rats) the half-life of the drug is about 24 hours
when administered orally using 12.5 mg/kg of ormeloxifene [124]. While in humans
(adult healthy females) the half-life of ormeloxifene is around 168 hours when
administered orally with either 30 mg or 60 mg of dose [126]. Recent studies have
repurposed ormeloxifene for its anti-cancer properties namely; it inhibits cell
proliferation/growth and motility, moreover, it was reported to block cell cycle and
induce apoptosis [127]. Previous studies suggest that ormeloxifene has strong anti-breast
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Figure 1-4. Structure of ormeloxifene.
Modified with permission. Kumar, R., et al., Selective estrogen receptor modulators
regulate stromal proliferation in human benign prostatic hyperplasia by multiple
beneficial mechanisms—action of two new agents. Investigational new drugs, 2012.
30(2): p. 582-593.
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cancer [113] and anti-head and neck cancer properties [128]. Ormeloxifene has been used
as an anti-neoplastic agent in MCF-7/ MDA MB-231 Estrogen Receptor (ER±ve) Human
Breast Cancer Cells (HBCCs) [129, 130]. Moreover, ormeloxifene works excellently in
combinational therapies as well with curcumin or resveratrol [131] and with glycine soya
[132] against breast cancer. Results from these studies suggest that ormeloxifene works
with both ER dependent and ER independent mechanisms and also it seems to work
through various different other pathways such as PI3K-Akt, STAT3 and SHH. Another
study shows that not only solid tumors but ormeloxifene also targets hematological
tumors such as chronic myeloid leukemia [133]. Our group has recently published that
ormeloxifene also has potent anti-pancreatic [134] and anti-ovarian [135] cancers
properties.
Nanomedicine
Nanotechnology is a newer therapeutic approach with great success over
traditional chemotherapy [136-139]. Nanoparticles have a suggested size range of 100300 nm [138, 140]. Size is the most important consideration while designing a
nanomedicine as it decides the fate of nanoparticle’s cellular uptake [141-143] and
biodistribution [144-146]. Particle size that is lesser than 5-10 nm is rapidly cleared by
kidneys [146, 147]. Also, particle size that is around 15 µm tends to accumulate in liver
and spleen [148-150]. Nanoparticle formulations provide targeted delivery of drugs along
with improved bioavailability in the system, thus, they are an attractive tool for evolving
newer treatment patterns for cancer [151-154]. Free drugs are not site-specific when
delivered to the body while modern methodology of nano-carriers facilitates the sitespecific targeted delivery of drugs [155-157]. Due to the leaky vasculature of the tumor
and enhanced permeation and retention (EPR) effect (Figure 1-5) [157-159], nanodrugs
can specifically be entrapped and accumulated into tumors [160-162]. Initial nanoparticle
formation was limited to liposomal and polymer based nanomaterial which is also called
first generation nanoparticles [163]. The first liposomal based nanoformulation that made
to the market was doxorubicin loaded liposomal nanoformulation called Doxil which
showed better therapeutic effects than free doxorubicin [164-166]. Polymer based
nanoformulation have also been studied [167, 168], for illustration, Poly(lactide-coglycolide) (PLGA) is an FDA-approved biodegradable and biocompatible polymer
employed for controlled drug delivery applications including anti-cancer drug delivery
[169-175]. Besides our research group, other investigators have also shown that using
PLGA nanoparticles to deliver chemotherapeutic drugs results in significant
improvement in inhibition of tumor burden in a wide variety of cancer models [176-181].
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Figure 1-5. Diagram shows EPR (enhanced permeation and retention) effect.
Modified with permission. Regehly, M., Photoinduced transfer processes in complex
carrier systems for photodynamic therapy. 2008, Humboldt-Universität zu Berlin,
Mathematisch-Naturwissenschaftliche Fakultät I.
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CHAPTER 2. EVALUATION OF ANTI-PROLIFERATIVE ACTIVITY OF
ORMELOXIFENE IN CERVICAL CANCER CELLS
Materials and Methods
Cell Culture
All cells (Caski and SiHa (HPV positive), C33A and HT3 (HPV negative)) were
obtained from ATCC. SiHa and C33A were cultured in DMEM medium supplemented
with 4500 mg/L glucose, 4.00 mM L- Glutamine, 10% heat inactivated FBS (Atlantic
Biologicals, Lawrenceville, G.A.), 1% (5 ml) sodium pyruvate, 1% (5ml) nonessential
amino acids and 1% (5 ml) 1× antibiotic/ antimycotic (Sigma, St. Louis MO). Caski cells
were maintained in RPMI medium containing 2.05 mM L-Glutamine, 10% heat
inactivated FBS and 1% (5 ml) 1× antibiotic/antimycotic. HT3 cells were grown in
McCoy’s 5A medium accommodated with L- Glutamine, 10% heat inactivated FBS and
1% (5 ml) antibiotic/antimycotic. All cells were incubated at 37º C in a humidified
atmosphere of 5% CO2.
Cell Proliferation Assays
We utilized four different cervical cancer cell lines for proliferation
measurements, Caski, SiHa, C33A and HT3 [129]. All cells were seeded at 5000 cells in
100 µL media per well in 96-well plates and allowed to attach overnight. Following day,
all 4 cervical cancer cell lines were treated with different micromolar concentrations (10
µM to 30 µM) of ormeloxifene (India). Ormeloxifene was dissolved in ETOH, diluted in
tissue culture medium and then added to 96-well plates for 48 hours incubation. After 48
hours the CellTiter96 Aqueous One Solution (Promega, Madison, WI) was added to 96well plates (20 µl/well), and the plates were incubated at 37º C for 2 hours and
absorbency was measured at 490 nm using a spectrophometer. Three readings were
obtained for each plate and proliferation results were normalized to control wells treated
with vehicle control ETOH. The experiment was performed three individual times in
duplicate each time.
Colony Forming Assays
All cervical cancer cells were seeded at 200 cells in 2 mL/well (Caski, SiHa and
C33A) and 500 cells in 2 mL/well (HT3) in 6 well plates and allowed to adhere
overnight. The following day, fresh media containing different micromolar
concentrations (2.5 µM to 10 µM) of ormeloxifene was added to the cells and cells were
maintained for next 14 days. On the 14th day cells were washed, fixed in cold methanol
and stained with hematoxylin (Thermo Fisher). Visible colonies (~50 cells) were counted
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and presented as compared to the vehicle (ETOH) control. Each experiment was done in
duplicate and repeated 3 times.
Real Time Cell Proliferation Kinetic Assay through xCELLigence System
To determine the effect of ormeloxifene on real time cellular proliferation/growth,
the xCELLigence system was used as described earlier [134]. xCELLigence system
measures the cellular events (cell proliferation, migration and invasion) in real time as it
is an electrical impedance-based method. In this experiment, plates (E plate VIEW 16,
ACEA Biosciences) were pre-incubated with 30 µL media for 30 min at 37º C and read
for background measurement. Afterwards, both Caski and SiHa cells were plated at 8 ×
103/chamber in 100 µL drug (20 µM ormeloxifene) containing media for cell
proliferation. Chamber plates were then incubated in xCELLigence instrument
chamber/unit at 37° C with 5% CO2 for real time cell proliferation. The experiment was
performed two times.
Statistical Methods
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software.
Results
Ormeloxifene Treatment Inhibits Cellular Proliferation of Various Cervical Cancer
Cells
To determine the effect of Ormeloxifene on cell growth of various cervical cancer
cells, we performed cell proliferation (MTS) assays with Caski and SiHa (HPV positive)
and C33A and HT3 (HPV negative). Cells were treated with ormeloxifene at different
micro-molar ranges for 48 hours. All four cells lines showed a significant decrease in a
dose- dependent manner and a drastic inhibitory effect was found between 20 µm and 30
µm doses (Figure 2-1, Figure 2-2, Figure 2-3 and Figure 2-4).
Ormeloxifene Treatment Inhibits Clonogenic Potential of Various Cervical Cancer
Cells
Colony forming ability is an essential property of cancerous cells toward
developing the tumor. Thus, we assessed colony forming assays to determine the long
term effect of ormeloxifene on cervical cancer cells. Ormeloxifene showed a significant
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Figure 2-1. Ormeloxifene decreased cellular proliferation of Caski cells.
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS
method was used to determine proliferation and absorbance was measured at 490 nm.
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3.
*p<0.05.

12

Figure 2-2. Ormeloxifene decreased cellular proliferation of SiHa cells.
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS
method was used to determine proliferation and absorbance was measured at 490 nm.
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3.
*p<0.05.
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Figure 2-3. Ormeloxifene decreased cellular proliferation of C33A cells.
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS
method was used to determine proliferation and absorbance was measured at 490 nm.
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3.
*p<0.05.
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Figure 2-4. Ormeloxifene decreased cellular proliferation of HT3 cells.
Cells were treated with ormeloxifene (10, 20, 25, and 30 µM) for 48 hrs and MTS
method was used to determine proliferation and absorbance was measured at 490 nm.
Results were normalized to the vehicle control (ETOH). Error bars show SEM, n=3.
*p<0.05.
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effect on clonogenic potential of all tested cervical cancer cell lines in a dose dependent
manner (Figure 2-5, Figure 2-6, Figure 2-7, Figure 2-8, Figure 2-9, Figure 2-10,
Figure 2-11 and Figure 2-12).
Real Time Growth Kinetics
We performed a real time growth kinetic study using xCELLigence system to
confirm ormeloxifene’s effect on proliferation of Caski and SiHa cells. The study was
conducted up to 160 hours and results were similar to MTS results. Ormeloxifene at 20
mM markedly decreased the cellular proliferation of both Caski and SiHa cells as
compared to vehicle control ETOH (Figure 2-13 and Figure 2-14).

Figure 2-5. Ormeloxifene inhibited clonogenic potential of Caski cells.
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X.
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Figure 2-6. Bar graph showing that Ormeloxifene inhibited clonogenic potential
of Caski cells.
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment.
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05.

Figure 2-7. Ormeloxifene inhibited clonogenic potential of SiHa cells.
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X.

17

Figure 2-8. Bar graph showing that Ormeloxifene inhibited clonogenic potential
of SiHa cells.
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment.
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05.

Figure 2-9. Ormeloxifene inhibited clonogenic potential of C33A cells.
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X.
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Figure 2-10. Bar graph showing that Ormeloxifene inhibited clonogenic potential
of C33A cells.
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment.
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05.

Figure 2-11. Ormeloxifene inhibited clonogenic potential of HT3 cells.
Qualitative representation of inhibited clonogenecity of cells. Images were taken at 200X.
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Figure 2-12. Bar graph showing that Ormeloxifene inhibited clonogenic potential
of HT3 cells.
Cells showed inhibited colony forming ability after 14 days of ormeloxifene treatment.
Results were normalized to the ETOH control. Error bars show SEM, n=3. *p<0.05.
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Figure 2-13. Ormeloxifene inhibited growth of Caski cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time growth
kinetics.

Figure 2-14. Ormeloxifene inhibited growth of SiHa cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time growth
kinetics.
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CHAPTER 3. DETERMINATION OF ANTI-MOTILITY PROPERTITES OF
ORMELOXIFENE IN CERVICAL CANCER CELLS
Materials and Methods
Agarose Bead Assay
To determine the effects of ormeloxifene on cellular motility of cervical cancer
cells we performed agarose bead assay as performed previously in our lab [182]. For this
experiment, 6-well plates were pre-coated with BSA-fibronectin. Cells (1X105) were
trypsinized and mixed into a 0.2% low melting point agarose solution. About 30 µL of
cells/agarose suspension was then plated onto fibronectin/bovine serum albumin coated
plates. The agarose-beaded plates were placed at 4º C for 10 min to set the agrose beads.
Complete growth medium was slowly added from the edges of the wells so that beads
were not disturbed and completely covered, and then plates were placed into a cell
culture incubator at 37º C with 5% CO2 . At 0, 12, 24 and 48 hrs the plates were removed
from the incubator and photographed under a phase-contrast microscope.
Boyden Chamber Cell Migration Assay
Cell migration assay was performed in a 96 well format HTS transwell plate from
Corning. Both Caski and SiHa cells were serum starved for overnight and next day plated
at 30,000 cells/well density in upper chambers containing 100 µL serum free culture
medium with different (10, 20 and 25 µM) concentrations of ormeloxifene treatment and
allowed to migrate towards FBS gradient to lower chamber with 10% FBS for next 24
hours. At the end of indicated time cells were fixed with 4% paraformaldehyde prepared
in PBS for 30 min at room temperature and stained with crystal violet for next 30 min.
Plates were then washed with running water to remove any excess staining. Cells in the
upper chamber were completely removed by cotton swab while wet and plates were air
dried overnight, next day, migrated cells were observed/ imaged by using light
microscope at 100X magnification.
Boyden Chamber Matrigel Cell Invasion Assay
For invasion assay, we used BD Biocoat Matrigel Invasion Chambers 24
transwell format (BD Biosciences). Invasion chambers/inserts were rehydrated with 500
µL serum free culture medium for 2 hours at 37º C. After 2 hours, 30,000 serum starved
cells (cells were serum starved for overnight), in 500 µL media, were plated in upper
chamber/insert. The lower wells were also filled up with 500 µL serum free media and
chamber containing plates were incubated at 37º C for next 24 hours. Ormeloxifene
treatment at 10, 20 and 25 µM concentrations in 500 µL serum free media was given to
the upper chambers next morning and serum free media in lower wells was replaced with
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10% FBS containing media. Cells were now allowed to invade across the matrigel
towards FBS gradient in the lower chamber for next 24 hours. At the end of given time
point, cells were fixed with 4% paraformaldehyde for 30 min at room temperature,
stained with crystal violet for another 30 min, washed with running water, and air dried.
Cells at the bottom side of chamber/insert (invaded cells) were imaged at 100X
magnification by using a light microscope.
Real Time Migration and Invasion Assays through xCELLigence System
The xCELLigence system was used for real time migration assessment of Caski
and SiHa cells. 16 chamber plates (CIM plate 16, ACEA Biosciences) were utilized for
this assay and the upper chambers were pre-incubated with 30 µL serum free media for
30 min at 37º C and the background reading was recorded. Next, Caski and SiHa cells
were plated at 3 × 104 per chamber with ormeloxifene (10, 20 and 25 µM) and its vehicle
control ETOH treatments in 100 µL serum free media. The bottom wells were provided
with 160 µL of 10% FBS media. Cells were allowed to settle for 30 min at room
temperature before plates were incubated in xCELLigence instrument chamber/unit at
37° C with 5% CO2. In invasion assay before pre-incubation, the upper chambers were
coated with 800 µg/mL matrigel (80 µL matrigel + 1920 µL serum free media) for 4
hours at 37º C. Each experiment was done twice.
Statistical Methods
All graphs were generated using GraphPad Prism5 software.
Results
Ormeloxifene inhibited cellular migration and invasion of cervical cancer cells. In
order to analyze the metastatic properties of cervical cancer cells after ormeloxifene
treatment, we performed agarose bead assay (Figure 3-1 and Figure 3-2), cell migration
(Figure 3-3 and Figure 3-4) and invasion assays (Figure 3-5 and Figure 3-6) using
Boyden chamber migration and Boyden chamber matrigel invasion assay. Both Caski and
SiHa cells showed an inhibition of motility/migration and invasion with an increase in
ormeloxifene concentration. A real time kinetic assessment for migration (Figure 3-7 and
Figure 3-8) and invasion (Figure 3-9 and Figure 3-10) was also performed using
xCELLigence system to confirm ormeloxifene’s effect on metastasis of Caski and SiHa
cells, and results were consistence with Boyden chamber assay. Furthermore, migratory
ability of cells was analyzed by using agarose bead and wound healing assays.
Ormeloxifene treatment again showed an inhibition of migration in dose and time
dependent manner in both cells.
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Figure 3-1. Ormeloxifene decreased cellular motility of Caski cells confirmed
through agarose bead assay.
Cells were treated with ormeloxifene up to 48 hours and images were taken at 100X.
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Figure 3-2. Ormeloxifene decreased cellular motility of SiHa cells confirmed
through agarose bead assay.
Cells were treated with ormeloxifene up to 48 hours and images were taken at 100X.

Figure 3-3. Ormeloxifene decreased cellular migration of Caski cells confirmed
through Boyden chamber migration assay.
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.
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Figure 3-4. Ormeloxifene decreased cellular migration of SiHa cells confirmed
through Boyden chamber migration assay.
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.

Figure 3-5. Ormeloxifene decreased cellular invasion of Caski cells confirmed
through Boyden chamber matrigel invasion assay.
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.

Figure 3-6. Ormeloxifene decreased cellular invasion of SiHa cells confirmed
through Boyden chamber matrigel invasion assay.
Cells were treated with ormeloxifene for 24 hours and images were taken at 100X.
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Figure 3-7. Ormeloxifene inhibited migration of Caski cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time migration
kinetics.

Figure 3-8. Ormeloxifene inhibited migration of SiHa cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time migration
kinetics.
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Figure 3-9. Ormeloxifene inhibited invasion of Caski cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time invasion
kinetics.

Figure 3-10. Ormeloxifene inhibited invasion of SiHa cells in real time.
Cells were exposed to ormeloxifene treatment and measured for real time invasion
kinetics.
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CHAPTER 4. ASSESSMENT OF APOPTOSIS INDUCING ABILITY OF
ORMELOXIFENE IN CERVICAL CANCER CELLS
Materials and Methods
Morphology Visualization with Phase Contrast Microscopy
Both cervical cancer cell lines were plated at 1X106 per 100 mm dish and allowed
to adhere for overnight. Next day, cells were treated with a range of ormeloxifene
concentrations (10, 20 and 25 μm) for 24 hours. At the end point cells were washed with
PBS and images were taken by using phase contrast microscopy at 200X.
Mitochondrial Membrane Potential
Reduction in mitochondrial membrane potential is the first and an important event
of intrinsic mitochondrial apoptotic cascade [183, 184]. Tetramethyl rhodamine ethyl
ester (TMRE) (Invitrogen) is an orange colored, positively charged dye that
premeabilizes through the mitochondrial membrane and sequesters into the healthy and
active mitochondria; thus, it is a widely used marker for mitochondrial membrane
potential [185]. Caski and SiHa cervical cancer cells at 1X106/plate were plated, allowed
to attach overnight and exposed to ormeloxifene treatment for 24 hours. At the indicated
time, cells were washed with PBS, incubated with 2 mL phenol red free medium
containing 50 nM TMRE at 37° C for 20 minutes, washed twice with PBS and supplied
with phenol red free medium and imaged using an Olympus microscope for the
qualitative assessment at 200X. After imaging, cells were washed with PBS, trypsinized
and analyzed with Accuri C6 flow cytometer in FL2 channel for the quantitative
measurement.
Cell Cycle Analysis
Telford method is a widely used method to detect different phases of cell cycle
[186]. Caski and SiHa cells were plated in 100 mm dish at the density of 1X106/plate and
allowed to adhere overnight. Next day, cells were exposed to ormeloxifene treatment at
10 and 20 µM concentration for 24 hours. After 24 hours, cells were trypsinized, washed
twice with PBS, fixed with 70% ice cold ETOH and saved at -20° C until further used.
Cells were stained with Propidium Iodide solution (Sigma-Aldrich, St. Louis, MO) 50 µg
in 1 mL Telford reagent at 1 mL for 1X106 cells for 4 hours at 4° C in the dark and
analyzed by Accuri C6 (BD Biosciences) flow cytometer in FL2 channel of red
fluorescence.
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Annexin V- 7AAD Staining
Annexin V labels the early apoptotic cells by binding to phosphatidylserine which
becomes exposed at the outside of the cell membrane as cells undergo apoptosis; thus, it
is a marker of early apoptosis [187] where as 7AAD is a marker of dead cells [188]. To
assess the induction of apoptosis, Caski and SiHa cervical cancer cells were plated
(1X106/plate) and allowed to attach overnight. Next morning, cells were treated with
different concentrations of ormeloxifene for 24 hours; both floaters and adherent cells
were collected, washed twice with PBS and stained with Annexin V and 7AAD (BD
Biosciences, San Diego, CA), 5 µL of each/100 µL of cell suspension for 20 min in the
dark at room temperature. After the incubation, cells were analyzed with Accuri C6 flow
cytometer in FL2 channel.
Reactive Oxygen Species (ROS)
Both Caski and SiHa cervical cancer cells were plated at 1X106/100 mm dish and
allowed to adhere overnight. Next morning, cells were exposed to 25 µM concentration
of ormeloxifene for 24 hours. After 24 hours cell were washed with PBS, trypsinized and
centrifuged at 1000 RPM for 5 min. The final cell pellet was resuspended in 1 mL of PBS
containing 20 µM DCFH-DA stain (a dye that is widely used to detect generation of ROS
[189]) and cells were then incubated for 20 minutes at 37° C. After 20 min cells were
analyzed with Accuri C6 flow cytometer (BD Biosciences) in FL2 channel for the
measurement of reactive oxygen species generation.
Immunoblotting
Caski and SiHa (1X106) cells were plated per 100 mm dish and allowed to attach
overnight. Next day cells were treated with different micromolar concentrations of
ormeloxifene for 24 hours. After treatment, both adherent and floating cells were
collected in 2x SDS lysis buffer (Santa Cruz Biotechnologies, Santa Cruz, CA), sonicated
and the protein concentration was normalized using SYPRO- Orange (Molecular Probes).
SDS – PAGE electrophoresis was done using 10% gradient gel and resolved proteins
were transferred onto PVDF (BioRad, Hercules, CA) membrane. HPV 16 E6/E7
(Abcam), PI3K, Akt, pAkt, Rb, PTPN13, Cyclin E and Cdk2 (Cell Signaling) and p53
(Santa Cruz) primary antibodies were used. The primary antibodies were detected by an
HRP-secondary antibody (anti-mouse or anti-rabbit) followed by incubation with the
Lumi-Light detection reagent (Roche, Nutley, NJ). Band intensity was normalized with
the β-actin loading control and the expression level was compared to the vehicle control
(ETOH).
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Statistical Methods
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software and ModFit (for cell cycle) software.
Results
Ormeloxifene Alters the Morphology of Cervical Cancer Cells
Phase contrast microscopic examination of cellular morphology suggested that
after indicated time period ormeloxifene promotes clear signs of apoptosis and alters the
morphology of treated cells. Cells started becoming round and detaching from the cell
culture plate surface; membrane blebbing and shrinkage of cytoplasm could also clearly
be seen in representative images of ormeloxifene treated cell (Figure 4-1 and Figure
4-2). These obvious signs are indicative of apoptotic morphological changes. On contrast,
the vehicle control ETOH treated cells did not have these changes in morphology.
Control group cells were in proper shape and size and attached to the surface of plate.
Ormeloxifene Induces Mitochondrial Membrane Potential
Decreased mitochondrial membrane potential (MMP) is a clear sign of induction
of apoptosis through the mitochondrial intrinsic pathway [190]. TMRE stains healthy and
active mitochondria; thus, it is an indicative of live cells. The visual inspection of TMRE
stain in Caski and SiHa cells after 24 hours of ormeloxifene treatment revealed that cells
started losing the intensity of TMRE stain with the increasing concentration of
ormeloxifene (Figure 4-3 and Figure 4-4). We also performed flow cytometry to
measure the quantitative depolarization of mitochondrial membrane in Caski and SiHa
cells and results were consistent. Ormeloxifene significantly decreased mitochondrial
membrane potential of both cells in dose dependent manner when compared to its vehicle
control ETOH (Figure 4-5 and Figure 4-6).
Ormeloxifene Induces Generation of Reactive Oxygen Species
Under stress conditions whether its drug treatment or radiation, tumor cells are
known to generate of reactive oxygen species (ROS) due to the oxidative stress.
Production of reactive oxygen species is one of the key phenomena which leads to
apoptosis. We used DCFH-DA stain to detect the amount of reactive oxygen species
generation after ormeloxifene treatment in Caski and SiHa cells. DCFH-DA
(dichlorodihydrofluorescein diacetate) is a very well-known stain that is used to detect
intracellular production of H2O2. After 24 hours of ormeloxifene treatment at 25 µM
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Figure 4-1. Ormeloxifene altered morphology of Caski cells.
Cells were observed and imaged under a phase contrast microscope at 200X after 24 hrs of
ormeloxifene treatment. Cells showed clear signs of apoptosis including blebbing and
shrinkage.

Figure 4-2.
Ormeloxifene altered morphology of SiHa cells.
Cells were observed and imaged under a phase contrast microscope at 200X after 24 hrs
of ormeloxifene treatment. Cells showed clear signs of apoptosis including blebbing and
shrinkage
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Figure 4-3. Ormeloxifene decreased mitochondrial membrane potential of Caski
cells.
Cells were exposed to ormeloxifene treatment for 24 hrs and afterwards stained with
TMRE and imaged with a fluorescent microscope at 200X. Cells showed a reduction in
TMRE fluorescence.
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Figure 4-4. Ormeloxifene decreased mitochondrial membrane potential of SiHa
cells.
Cells were exposed to ormeloxifene treatment for 24 hrs and afterwards stained with
TMRE and imaged with a fluorescent microscope at 200X. Cells showed a reduction in
TMRE fluorescence.
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Figure 4-5. Ormeloxifene decreased mitochondrial membrane potential (MMP) of
Caski cells.
Cells were treated with ormeloxifene for 24 hrs and stain with TMRE dye to detect the
healthy mitochondria. Results were compared to vehicle control ETOH. Error bars show
SEM, n=3. *p<0.05.
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Figure 4-6. Ormeloxifene decreased mitochondrial membrane potential (MMP) of
SiHa cells.
Cells were treated with ormeloxifene for 24 hrs and stained with TMRE dye to detect the
healthy mitochondria. Results were compared to vehicle control ETOH. Error bars show
SEM, n=3. *p<0.05.
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concentration, both cell lines showed elevated levels of H2O2 generation when compared
to vehicle control ETOH as confirmed by higher intensity levels of DCFH-DA stain
(Figure 4-7 and Figure 4-8).
Ormeloxifene Induces Apoptosis in Cervical Cancer Cells
We confirmed the ormeloxifene’s ability to induce the apoptosis by probing the
cells with Annexin V and 7AAD stain. As Annexin V denotes the early apoptosis and
7AAD marks the dead cells. Flow cytometer results illustrated that both Caski and SiHa
cells after 24 hours of ormeloxifene treatment at 20 and 25 µM concentration showed a
marked increase in the percentage of Annexin V positive cell population (Figure 4-9,
Figure 4-10, Figure 4-11 and Figure 4-12), confirming the early apoptosis phase. We
also observed greater percentage of AnnexinV-7AAD (double stain) positive cells in
higher concentration (25 µM ormeloxifene) treated Caski cells (Figure 4-9) when
compared to its vehicle control ETOH, but in a dose dependent manner in SiHa cells
(Figure 4-10), confirming the late apoptosis phase.
Ormeloxifene Arrest Cell Cycle in G1-S Transition by Regulating the Expression
Level of Transition Related Proteins
We further validated ormeloxifene’s ability to induce apoptosis by performing the
cell cycle arrest assay to determine the cell population at different phases of cell cycle.
Caski and SiHa cells were treated with 10 and 20 µM of ormeloxifene for 24 hours and
stained with Propidium Iodide. Cells showed a blockage of progression at G1-S transition
(Figure 4-13 and Figure 4-14). Furthermore, we confirmed the cell cycle arrest at G1-S
transition by probing for the two transition related molecules Cyclin E and its dependent
kinase; cyclin dependent kinase 2 (Cdk2) utilizing immunoblotting. Ormeloxifene
significantly decreased the expression of both the proteins at 20 µM concentration when
compared to the vehicle control ETOH (Figure 4-15 for immunoblots; Figure 4-16 and
Figure 4-17 for density quantification).
Ormeloxifene Downregulates PI3K-Akt Pathway
PI3K-Akt cell survival oncogenic pathway is overly expressed in cervical cancer
cells. The pathway is required for cell cycle progression from G1 phase to S phase.
Inhibition of PI3K-Akt pathway is an important tool for developing the treatment
strategies for cervical cancer. We utilized immunoblotting assay to evaluate the inhibitory
effects of ormeloxifene on PI3K-Akt pathway. Ormeloxifene decreased the total Akt
expression slightly but phosphorylated and active form of Akt (pAkt) and PI3K were
decreased markedly (Figure 4-18). Figure 4-19, Figure 4-20 and Figure 4-21 indicate
the densitometric analysis of band intensity of immunoblots showed in Figure 4-18.
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Figure 4-7. Ormeloxifene enhanced the generation of reactive oxygen species
(ROS) in Caski cells.
Cels were treated with ormeloxifene for 24 hrs and stain with DCFH-DA dye to detect
H2O2 formation. Results were compared to vehicle control ETOH. Error bar shows SEM,
n=3. *p<0.05.
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Figure 4-8. Ormeloxifene enhanced the generation of reactive oxygen species
(ROS) in SiHa cells.
Cells were treated with ormeloxifene for 24 hrs and stain with DCFH-DA dye to detect
H2O2 formation. Results were compared to vehicle control ETOH. Error bar shows SEM,
n=3. *p<0.05.
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Figure 4-9. Cell population diagram of Caski cells obtained with Flow Cytometer
representing percentage of cells stained with either Annexin V or 7AAD or both or
none.

Figure 4-10. Cell population diagram of SiHa cells obtained with Flow Cytometer
representing percentage of cells stained with either Annexin V or 7AAD or both or
none.
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Figure 4-11.Ormeloxifene induced apoptosis of Caski cells.
Cells were treated with ormeloxifene for 24 hours and analyzed by flow cytometry using
Annexin V and 7AAD dyes. Results were compared to vehicle control ETOH. Error bars
show SEM, n=3. *p<0.05.
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Figure 4-12. Ormeloxifene induced apoptosis of SiHa cells.
Cells were treated with ormeloxifene for 24 hours and analyzed by flow cytometry using
Annexin V and 7AAD dyes. Results were compared to vehicle control ETOH. Error bars
show SEM, n=3. *p<0.05.
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Figure 4-13. Ormeloxifene arrested cell cycle at G1-S transition in Caski Cells.
Cell cycle population diagram of Caski cells obtained with ModFit software representing
percentage of different cell population stained with propidium iodide.

Figure 4-14. Ormeloxifene arrested cell cycle at G1-S transition in SiHa cells.
Cell cycle population diagram of SiHa cells obtained with ModFit software representing
percentage of different cell population stained with propidium iodide.
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Figure 4-15. Ormeloxifene downregulated the expression levels of Cyclin E and
Cdk2 in Caski cells.
Cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed to
detect Cyclin E and Cdk2 proteins. β-actin was used as a loading control.
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Figure 4-16. Densitometric quantitation of band intensity of Cyclin E.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = Relative
Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 4-17. Densitometric quantitation of band intensity of Cdk2.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars = Relative
Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 4-18. Ormeloxifene downregulated the expression levels of PI3K/Akt
pathway in Caski cells.
Cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed to
detect PI3K, Akt and pAkt proteins. β-actin was used as a loading control.
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Figure 4-19. Densitometric quantitation of band intensity of PI3K.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.

48

Figure 4-20. Densitometric quantitation of band intensity of pAkt.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 4-21. Densitometric quantitation of band intensity of Akt.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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CHAPTER 5. ANALYSIS OF ORMELOXIFENE’S EFFECT ON HPV
REGULATION ONCOGENESIS IN CERVICAL CANCER
Materials and Methods
Quantitative PCR
1X106 Caski cells were plated per 100 mm dish and allowed to attach overnight.
After 24 hours cells were treated with ormeloxifene at 2 different micromolar
concentrations (10 µM and 20 µM) for 6 hours. After indicated time, adherent cells were
collected and RNA was extracted with the Qiagen RNeasy kit (Qiagen Inc., Valencia,
CA). Reverse transcription was performed with the High Capacity RNA to cDNA kit and
amplified with SYBR Green PCR master mix (both from Applied Biosystems). The
cDNA was amplified with primers specific for HPV16 E6, HPV16 E7 and β2microglobulin. E6-F: caaaccgttgtgtgatttgttaatta; E6-R: gctttttgtccagatgtctttgc; E7-F:
ccggacacagcccattacaa; E7-R: cgaatgtctacgtgtgtgctttg; β2M-F: tgagtatgcctgccgtgtga;
β2M-R: tgatgctgcttacatgtctcgat [130]. Each reaction was performed in duplicate with a
MyiQ single color real time PCR thermo cycler and analyzed with Genex (Microsoft
Excel macro provided by BioRad). The results were first normalized to the endogenous
control (β2-microglobulin) and then the expression level was scaled to the vehicle control
(ETOH).
Immunoblotting
Caski and SiHa (1X106) cells were plated per 100 mm dish and allowed to attach
overnight. Next day cells were treated with different micro molar concentrations of
ormeloxifene for 24 hours. After treatment, both adherent and floating cells were
collected in 2x SDS lysis buffer (Santa Cruz Biotechnologies, Santa Cruz, CA), sonicated
and the protein concentration was normalized using SYPRO- Orange (Molecular Probes).
SDS – PAGE electrophoresis was done using 10% gradient gel and resolved proteins
were transferred onto PVDF (BioRad, Hercules, CA) membrane. HPV 16 E6/E7
(Abcam), PI3K, Akt, pAkt, Rb, PTPN13, Cyclin E and Cdk2 (Cell Signaling) and p53
(Santa Cruz) primary antibodies were used. The primary antibodies were detected by an
HRP-secondary antibody (anti-mouse or anti-rabbit) followed by incubation with the
Lumi-Light detection reagent (Roche, Nutley, NJ). Band intensity was normalized with
the β -actin loading control and the expression level was compared to the vehicle control
(ETOH).
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Statistical Methods
Statistical analysis was determined by using an unpaired, two tailed student’s t-test.
The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software.
Results
Ormeloxifene Decreases the Expression of HPV Oncogenes E6 and E7
Oncogenes E6 and E7 are responsible for continuous cell division which results in
development of cervical cancer. Expression of human papillomavirus E6 and E7 is a very
important consideration for cervical cancer treatment. Quantitative RT – PCR was
performed to determine the expression of HPV oncogenes E6 and E7 in Caski cells.
Ormeloxifene significantly inhibits the expression of E6 and E7 after 6 hours of
Ormeloxifene treatment (10 µM and 20 µM doses) (Figure 5-1 and Figure 5-2). The
indicated treatment was compared with vehicle control ETOH. We also assessed the
downregulation of oncogenic signaling at the translational level by performing
immunoblotting. Both oncoproteins showed a marked reduction in the expression level
compared to the vehicle control ETOH (Figure 5-3). Figure 5-4 and Figure 5-5 indicate
the densitometric analysis of band intensity of Figure 5-3.
Ormeloxifene Restores the Tumor Suppressor Signaling
The oncogenic properties of HPV E6 and E7 are increased when E6 and E7 bind
to the suppressor proteins p53, Rb and PTPN13. Ormeloxifene’s effect on these tumor
suppressing molecules was determined by the immunoblotting assays. We treated Caski
cervical cancer cells with 10 and 20 µM concentration of ormeloxifene for 24 hours and
probed for three tumor suppressor proteins. We observed a slight but noticeable decrease
in the expression of wild type p53, but Rb and PTPN13 proteins also showed a marked
decrease in the expression after ormeloxifene treatment at 20 µM dose (Figure 5-6).
Figure 5-7, Figure 5-8 and Figure 5-9 indicate the densitometric analysis of band
intensity of Figure 5-6.
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Figure 5-1. Ormeloxifene decreased HPV E6 mRNA.
Caski cells were treated with ormeloxifene for 6 hrs and mRNA level of HPV E6 was
determined by quantitative PCR. Expression levels were normalized to a house keeping
gene (β-2-Microgloblin) and scaled to the vehicle control (ETOH). Bars = Relative
Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 5-2. Ormeloxifene decreased HPV E7 mRNA.
Caski cells were treated with ormeloxifene for 6 hrs and mRNA level of HPV E7 was
determined by quantitative PCR. Expression levels were normalized to a house keeping
gene (β-2-Microgloblin) and scaled to the vehicle control (ETOH). Bars = Relative
Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 5-3. Ormeloxifene inhibited HPV E6 and E7 proteins.
Caski cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed
to detect HPV E6 and E7 proteins. β-actin was used as a loading control.
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Figure 5-4. Densitometric quantitation of band intensity of HPV E6.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.

56

Figure 5-5. Densitometric quantitation of band intensity of HPV E7.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 5-6. Ormeloxifene restored the expression levels of p53, Rb and PTPN13
tumor suppressor proteins.
Caski cells were treated with ormeloxifene for 24 hrs and immunoblots were preformed
to detect p53, Rb and PTPN13 proteins. β-actin was used as a loading control.
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Figure 5-7. Densitometric quantitation of band intensity of p53.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 5-8. Densitometric quantitation of band intensity of Rb.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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Figure 5-9. Densitometric quantitation of band intensity of PTPN13.
Band intensity was normalized to β-actin and scaled to the ETOH control. Bars =
Relative Expression Level, Error bars show SEM, n=3. *p<0.05.
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CHAPTER 6. IN VITRO EXAMINATION OF ORMELOXIFENE WITH
RADIATION AS A COMBINATION THERAPY
Materials and Methods
Cell Proliferation Assays
In order to analyze the combinatorial effects of ormeloxifene with radiation we
utilized Caski cells. Cells were seeded at 200,000 cells in 2 mL media per well of 6-well
plates and allowed to adhere overnight. Next day the treatment was performed in two
different conditions. The first set of cells was pre-treated with 10 µM ormeloxifene for 24
hours and then next morning exposed to 4 Gy dose of radiation for another 24 hours. The
second set of cells was co-treated with 10 µM ormeloxifene and 4 Gy dose of radiation at
the same time for next 24 hours. A Biological X-ray irradiator (Radiation Source,
Alpharetta, GA) was used to irradiate the cells. After the indicated time cells were
trypsized, washed with PBS and counted with coulter counter (Beckman coulter counter,
Life Sciences). Experiment was done in triplicate.
Colony Forming Assays
Caski cervical cancer cells were seeded at 200 cells in 2 mL/well in 6 well plates
and allowed to attach overnight. Following day, cells were pretreated with different
concentrations of ormeloxifene (2, 4, 6 and 8 µM) for 6 hours. After 6 hours, cells were
exposed to radiation at 4 Gy dose. Cells were then maintained for next 12-14 days. On
the day of termination, cells were washed, fixed in cold methanol and stained with
hematoxylin (Thermo Fisher). Visible colonies (~50 cells) were counted manually. Each
experiment was done in triplicates and repeated 3 individual times.
Statistical Methods
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software.
Results
Ormeloxifene treatment induced radio-sensitization in Caski cervical cancer cells.
We performed short term and long term studies to analyze ormeloxifene’s effect in radiosensitization in Caski cells. We observed that after 24 hours of radiation, number of live
cells significantly decreased with both pretreatment (Figure 6-1 and Figure 6-2) and cotreatment (Figure 6-3 and Figure 6-4) of ormeloxifene when compared with radiation
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Figure 6-1. Caski cells were pretreated with ormeloxifene and exposed to
radiation.
Combination treatment of ormeloxifene and radiation showed an inhibitory effect on
cellular growth/ proliferation. Images were taken at 100X.
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Figure 6-2. Caski cells were pretreated with ormeloxifene and exposed to
radiation and cells were counted with Coulter counter.
Results were normalized to the ETOH control (for ormeloxifene) and to radiation and
free ORM (for combination). Error bars show SEM, n=3. *p<0.05. Combination
treatment of ormeloxifene and radiation showed an inhibitory effect on cellular growth/
proliferation.
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Figure 6-3. Caski cells were treated with ormeloxifene and exposed to radiation
simultaneously.
Combination treatment of ormeloxifene and radiation showed an inhibitory effect on
cellular growth/ proliferation. Images were taken at 100X.
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Figure 6-4. Caski Cells were treated with ormeloxifene and exposed to radiation
simultaneously and cells were counted with Coulter counter.
Results were normalized to the ETOH control (for ormeloxifene) and to; radiation and
free ORM (for combination). Error bars show SEM, n=3. *p<0.05. Combination
treatment of ormeloxifene and radiation showed an inhibitory effect on cellular growth/
proliferation.
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alone and ormeloxifene alone treatment groups. However, the co-treatment showed more
inhibition of cellular growth than pretreatment. The results were consistent with long
term pretreatment of ormeloxifene and significantly sensitized Caski cells to radiation as
confirmed by decreased number of colonies when compared to radiation alone and
ormeloxifene alone treated groups (Figure 6-5). The quantification of colonies is
presented in Figure 6-6.

Figure 6-5. Combination treatment of ormeloxifene and radiation reduced the
clonogenic potential of Caski cells.
Cells were pretreated with ormeloxifene and exposed to radiation. Cells were observed
under phase contrast microscope and images were taken at 200X.
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Figure 6-6. Bar graph showing that combination treatment of ormeloxifene and
radiation reduced the clonogenic potential of Caski cells.
Cells were pretreated with ormeloxifene and exposed to radiation. Results were
normalized to the ETOH control (for ormeloxifene) and to radiation and free ORM (for
combination). Error bars show SEM, n=3. *p<0.05.
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CHAPTER 7. DEVELOPMENT AND PHYSICOCHEMICAL
CHARACTERIZATION OF ORMELOXIFENE LOADED PLGA
NANOPARTICLES*
Materials and Methods
Synthesis of PLGA-ORM NPs
PLGA-ORM NPs were prepared by following a nano-precipitation technique
[176, 177] with a modified protocol (Figure 7-1). The stable PLGA-ORM NP suspension
was obtained using polymer stabilizers, poly(vinyl alcohol) (PVA) and poly(L-lysine)
(PLL). Briefly, to 20 mL aqueous 1% PVA solution, 90 mg of PLGA and 20 mg ORM
were dissolved in 8-10 mL acetone that was added drop-wise using a 1 mL pipette over
10 min under a constant stirring on a magnetic stir plate at 500 rpm. This process leads to
a milky-white suspension. This suspension was left overnight at room temperature in the
chemical fume hood under stirring condition, allowing for complete evaporation of the
acetone. Then, to this suspension, 10 mg PLL in 5 mL water was added and stirred at 500
rpm for 6 hr. The resulted PLGA-ORM NPs in suspension were purified and recovered
by ultracentrifugation at 20,000 rpm for 2 hr at 4º C, three times, using a Rotor 30.50 on
an Avanti J-30I Centrifuge (Beckman Coulter, Fullerton, CA), followed by re-suspension
in ultra-purified water and sonication on ice for 1 min (using a probe sonicator). Then the
supernatant containing PLGA-ORM NPs was transferred to a sterile cryo-vial, frozen at 80º C for 2 hr, and immediately lyophilized for 2-3 days using the Labconco Freeze Dry
System (−48º C, 133 × 10−3 mBar; Labconco, Kansas City, MO). The lyophilized vials
were stored in a 4º C cold room for further in vitro and in vivo use. This formulation was
named PLGA-ORM 20. Similarly, PLGA-ORM formulations with 5, 10, 15, and 25 mg
ORM were prepared and termed as PLGA-ORM 5, PLGA-ORM 10, PLGA-ORM 15,
and PLGA-ORM 25, respectively. Additionally, parent PLGA NPs were also prepared
without ORM that served as a control for all in vitro and in vivo experiments.
PLGA-ORM NPs Characterization
Particle Size
PLGA-ORM NPs were characterized for the surface morphology and size of
particles using a JEOL-1210 transmission electron microscope (TEM) (JEOL Ltd.,
Tokyo, Japan) operating at 60 kV. For this, 50 µL suspension of 1 mg/mL PLGA-ORM
NPs was carefully dispersed on 200 mesh formvar-coated copper TEM-grid (grid size:
----------------------------* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-1. Diagram showing preparation method (nano-precipitation) of PLGAORM nanoformulation.
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97 μm) (Ted Pella, Inc., Redding, CA), followed by staining with 2% w/v of uranyl
acetate solution. The excess solution on the grid was removed by air drying. Then,
particles on the TEM-grid were imaged under TEM. We also used a dynamic light
scattering system to confirm particle size.
Drug Loading
To determine ORM loading, freshly prepared PLGA-ORM NPs were centrifuged
three times at 20,000 rpm for 2 hr at 4º C using Avanti J-30I Centrifuge, followed by resuspension in ultra-purified water and sonication on ice for 1 min. The supernatant was
removed, the pellet was re-suspended, lyophilized, and ORM from pellet was extracted
for 2 days with 1 mL of acetonitrile. The concentration of ORM in the extract was
analyzed using an UltiMate high-performance liquid chromatography (HPLC) (Dionex
Corporation) equipped with UltiMate 3000 injector, RS variable wavelength detector, and
an Acclaim polar advantage column of 3 μm 120 Å (4.6 × 150 mm). The mobile-phase
consisted of a mixture of 1% citric acid:acetonitrile (40:60, v/v). 50 µL of the extracted
samples were injected using an auto injector (Model 508, Beckmann Instruments) and
peaks were analyzed using a UV detector at 279 nm. The retention time was observed at
~18-20 min [191]. A linear calibration curve in the range of 1 to 10 µg/mL was obtained
at the same working condition for ORM. From this data, the ORM loading content was
calculated as follows:
Fourier Transform Infra-Red
FT-IR spectra of PLGA-ORM NPs were obtained using a Fourier Transform
infra-red (FT-IR) microscope (Smiths Detection, Danbury, CT). The spectra data, 4,000–
750 cm-1, was acquired at a scanning speed of cm-1 for 32 scans by placing lyophilized
PLGA-ORM NPs powder on the attenuated total reflection objective. The final data is
reported as an average data of 32 scans.
Thermal Analysis
Thermal analysis of PLGA-ORM NPs was carried out using differential scanning
calorimetry (DSC) and thermo-gravimetric analyzer (TGA) to investigate the physical
status and thermal profile. Both DSC and TGA profiles were accomplished on a Q50
TGA (TA Instruments, New Castle, DE) under dry nitrogen atmosphere (a flow rate of
10 mL/min) from 25° C to 700° C at the heating rate of 10° C/min.
In Vitro Drug Release (Dialysis Bag Method)
Dialysis membrane bag based drug release method [1] (Figure 7-2) was
employed to evaluate release of ormeloxifene (ORM) from PLGA-ORM 20
nanoformulation in PBS containing 0.1% (wt/vol) Tween-80 (PBS-T). In detail, 1 mL of
180 µg ORM/mL PLGA-ORM 20 suspension was placed in a dialysis membrane bag
(molecular weight cut off size, 12 kDa, Sigma–Aldrich Co., St. Louis, MO) which was
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Figure 7-2.

Representation of in vitro drug release in house system.
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immersed in 3 mL PBS-T, pH 7.4 in a tube at 37° C and rotated at 100 rpm on an orbital
shaker. The released drug from PLGA-ORM 20 into PBS-T was estimated at indicated
time points [1 hr, 3 hrs, 6 hrs, day 1 (24 hrs), day 3 (72 hrs), day 5 (120 hrs), and day 7
(168 hrs)] using acetonitrile for drug extraction. The released ORM was analyzed by
Waters HPLC Alliance system equipped with an e2695 separations module and a Waters
2998 photo-diode array (PDA) detector (Milford, MA, USA). Samples were analyzed
using a Waters HPLC system which has an auto injector and the instrument was operated
by use of Empower2® software (Milford, MA, USA). Components were separated on a
Waters C18 reversed- phase column (Milford, MA, USA) with 300 mm × 4.6 mm
dimensions and 5 μm particle size. A linear calibration curve in the range of 0.1 to 10
µg/mL was obtained as identical to drug release process and calculated the released drug
from PLGA-ORM formulation. The data is represented as percent release.
Colloidal Stability of Nanoparticles in Whole Human Serum Albumin
(WHSA)
Before testing nanoparticles in vivo, it is important to confirm in vitro stability of
nanoparticles with human serum. If nanoparticles are not compatible with serum, they
aggregate and result in higher absorbance value. To study human serum compatibility of
our formulation, we utilized Spectrophotometer absorption method as due to the turbidity
of the serum, dynamic light scattering method is not very useful for authentication. For
this experiment, PLGA-ORM was finally prepared at 1 mg/mL concentration; from this
stock solution we incubated 100 µL of this novel formulation with 100 µL of whole
human serum albumin at 37º C for different time points from 0 hr to 48 hrs. At each time
point, absorbance was measured at 560 nm utilizing Cytation 3 imaging multi microplate
reader (BioTek).
Statistical Methods
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software and Statistical Package for the Social Sciences, version 11.5
(SPSS Inc., Chicago, IL).
Results
The primary objectives of this study were to improve the anti-cancer activity of
ORM, using a nanoparticle formulation (Figure 7-3) [192], and to examine its efficacy in
human cervical cancer cell line and xenograft mouse models. The motive to make an
ORM nanoformulation is that; nanoparticles (NPs) are known to preferentially reach and
accumulate in tumor tissue(s) due to leaky vasculature by the Enhanced Permeation and
Retention (EPR) effect [193, 194]. For such phenomenon, a better example is Abraxane®,
which has been widely used in the clinic for the treatment of various types of cancers,

73

Figure 7-3. Schematic of PLGA-ORM NP formulations.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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including pancreatic cancer. This confirms that the nanodrug formulation(s) may have
superior outcome over traditional chemotherapy in clinical oncology. Therefore, we have
generated a PLGA-based ORM nanoparticle formulation, PLGA-ORM NPs. The
selection of the PLGA NP-based formulation to deliver ORM is due to the fact that the
PLGA co-polymer has shown promising results in in vitro, in vivo, pre-clinical, and
human studies (for example, BIND-014, a docetaxel PLGA NP formulation). Based on
these facts, we have engineered an optimized PLGA-ORM NP formulation, composed of
a PLGA core that is subsequently coated with poly(vinyl alcohol) (PVA) and poly(llysine) (PLL) for efficient delivery and targeting of ORM to cancer cells. This
formulation (Figure 7-3), has several unique properties: (a) the PLGA core is capable of
loading and releasing ORM in sustained manner, more importantly, it was approved by
US Food and Drug Administration, (b) PVA, a widely used stabilizer for most of the
polymer NP formulation(s), supports stability of formulation over 6 month(s) and avoids
non-specific adsorption of human serum proteins in in vivo condition, (c) PLL promotes
cellular internalization and is less toxic compared to other polycationic polymers, and (d)
amine functional groups on NPs (PLL) are useful for antibody conjugation through a
PEG-linker, notably, the N-Hydroxysuccinimide (NHS) group for targeting tumor/cancer
cells.
Characterization of PLGA-ORM NPs
PLGA and PLGA-ORM NP formulations (PLGA-ORM 5, PLGA-ORM 10,
PLGA-ORM 15, PLGA-ORM 20, and PLGA-ORM 25) were successfully prepared by
increasing amounts of ORM in the composition (0 to 25 mg). Drug loading was assessed
by HPLC method that indicated all the nanoformulations resulted in ORM encapsulation
(> 80-90% encapsulation efficiency). Based upon loading analysis, we selected PLGAORM 20 formulation for all our further cellular work. All formulations exhibit
homogeneous spherical shapes and smooth surfaces without cracks (Figure 7-4, Figure
7-5, Figure 7-6, Figure 7-7, Figure 7-8 and Figure 7-9) [192]. The mean particle size of
PLGA or PLGA-ORM NPs was found to be 30.8 ± 1.5 nm (PLGA NPs), 68.4 ± 1.5 nm
(PLGA-ORM 5), 70.8 ± 4.5 nm (PLGA-ORM 10), 87.3 ± 1.5 nm (PLGA-ORM 15),
101.4 ± 1.5 nm (PLGA-ORM 20), and 175.2 ± 1.5 nm (PLGA-ORM 25). The size of
PLGA-ORM NP formulations was mostly between 50 nm to 250 nm and was narrowly
distributed in each formulation. (Figure 7-10) [192]. We also measured particle size
using DLS method; data illustrated a particle size under 280 nm for all formulations
(Figure 7-11). It was noticed that the formulation particle size increased when drug
loading used for the particle preparation increased. However, all these formulations were
small enough in size and suitable for tumor specific accumulation via the EPR effect
[195]. To confirm the ORM existence in PLGA-ORM NP formulations, FT-IR (Figure
7-12), DSC (Figure 7-13), and TGA (Figure 7-14) studies were conducted [192]. In the
FT-IR spectrum of PLGA NPs (Figure 7-12, navy blue line), the intense peaks were
found at 1741 cm-1, 1181 cm-1, and 1010 cm-1 due to C=O stretching of ester, C-O
stretching of ester, and glycosidic (C–O–C/C–C/C–O) stretch vibrations. Because ORM
has similar major functional groups in its structures (Figure 7-12, black line), after
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Figure 7-4. Representative TEM images of PLGA alone nanoparticles and Scale
bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-5. Representative TEM images of PLGA-ORM 5 nanoparticles and
Scale bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-6. Representative TEM images of PLGA-ORM 10 nanoparticles and
Scale bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-7. Representative TEM images of PLGA-ORM 15 nanoparticles and
Scale bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-8. Representative TEM images of PLGA-ORM 20 nanoparticles and
Scale bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-9. Representative TEM images of PLGA-ORM 25 nanoparticles and
Scale bars on TEM images equal 200 nm.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-10. Evaluation of nanoparticle size from TEM images using ImageJ
software, data represents an average of at least 20 particles in two different fields of
view in TEM images.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-11. PLGA-ORM particle size representation using DLS system.
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Figure 7-12. FT-IR spectra of ORM, PLGA NPs and PLGA-ORM NP
formulations confirmed that ormeloxifene is successfully encapsulated in PLGA
core.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-13. DSC endothermic curves of PLGA and PLGA-ORM NP
nanoformulations confirmed that ormeloxifene is successfully encapsulated in
PLGA core.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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Figure 7-14. Thermogravimetric weight loss curves of PLGA and PLGA-ORM NP
nanoformulations suggested ORM’s successful incorporation in the PLGA-ORM
NP formulation.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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encapsulation no additional peaks appeared in FT-IR spectra of PLGA-ORM NPs
(Figure 7-12), red to magenta lines, upwards). On the other hand, additional peaks
were not attained in FT-IR after ORM encapsulation due to a higher degree of miscibility
of ORM in the PLGA polymer matrix [196]. On the other hand, ORM may have been
masked by the bands produced by the PLGA polymer matrix. This behavior was further
confirmed with DSC analysis (Figure 7-13). DSC curves of pure PLGA NP formulation
exhibit an endothermic peak at ~ 79º C (Figure 7-13, black line), indicative of the glass
transition temperature of the formulation. Due to incorporation of ORM in the PLGAORM formulations, an exothermic peak appeared at ~ 58º C (Figure 7-13, red to
magenta lines, downwards). Because of its superior blending of PLGA NPs and ORM
in the PLGA-ORM NP formulations, PLGA glass transition peak disappeared or lowered
the PLGA glass transition temperature. This indicates that ORM in nanoformulations is
highly miscible. On the other hand, it appears that there is a significant reduction of
crystallinity of the formulation. The presence of ORM in nanoformulations was further
confirmed by TGA (Figure 7-14). The significant weight loss of PLGA NPs begins at
250º C to 580º C (Figure 7-14, black line). This behavior is further accelerated due to
the presence of ORM in PLGA-ORM nanoformulations (Figure 7-14, red to magenta
lines). Approximately, 55% and 80% weight loss were observed at 350º C and 550º C for
PLGA NP formulations while PLGA-ORM NP formulations show 74% and 95%,
respectively. Such greater weight loss is attributed to the presence of ORM in the
nanoformulations.
In vitro Release Profile
In vitro drug release profile is an important experiment for developing a
successful nanoformulation that qualifies for its use in vivo. Free drugs are readily
available for the system so they can have a quick effect but soon they get cleared from
the system. On the other hand nanoformulations release at the sustained rate, thus, carry
better therapeutic efficacy over free drugs. The release profile of ORM from PLGAORM 20 is presented in (Figure 7-15) [192]. The release of ORM is relatively rapid at 13 hrs and thereafter the release pattern is gradual and sustained.
Serum Stability of PLGA-ORM
Nanoparticles can easily aggregate or disintegrate or leak drug upon their
administration to in vivo system where particles come in contact with systemic
blood/serum. Therefore, it becomes necessary to evaluate stability of nanoparticles with
serum. We utilized whole human serum to assess the stability of our PLGA-ORM
nanoformulation. Results from absorption method indicated that this formulation is
highly stable with human serum as confirmed by no or negligible change absorbance
(Figure 7-16). Higher absorbance value is an indicative of higher degree of aggregation.
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Figure 7-15. Sustained in vitro release profile of PLGA-ORM.
Reprinted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.

Figure 7-16. Whole human serum stability profile of PLGA-ORM.
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CHAPTER 8. EVALUATION OF IN VITRO UPTAKE AND ANTIPROLIFERATIVE ACTIVITY OF PLGA-ORM
Materials and Methods
Cellular Internalization of Nano-ORM in Caski and SiHa Cervical Cancer Cells
To determine the cellular uptake of nanoparticles in cervical cancer cells, we
incorporated 5 mg coumarin-6 green fluorescent dye with our PLGA-ORM formulation.
200,000 cells were seeded in 6-well plate and allowed to attach overnight. Next morning,
cells were treated with coumarin-6 labeled PLGA-ORM and its vehicle control PLGA
NPs respectively for 1 and 3 hours, washed twice with PBS and plates were imaged with
a fluorescence microscope (Nikon Eclipse, Melville, NY). After imaging cells were
trypsinized, washed with PBS and collected for uptake measurement by flow cytometer.
Fluorescence levels from cells were measured with FL1 channel in Accuri C6 flow
cytometer (BD Biosciences, CA)
Transmission Electron Microscopy (TEM)
For the uptake analysis by TEM, we plated Caski and SiHa cells at 200,000/well
in 6 well plates and allowed to adhere overnight. Next morning, cells were treated with
free ORM, PLGA-ORM and their vehicle controls ETOH and PLGA NPs respectively
for 3 hours. After 3 hours, cells were trypsinized, washed with PBS, centrifuged and the
pellet was collected. After the final pellet collection, it was fixed with 2% glutaraldehyde
buffer, rinsed with 100 mM Na-cacodylate and further processed for TEM analysis.
Cell Association Study
Both cells were plated in 60 mm dish for the overnight attachment. Next day, cells
were pre-incubated either at physiological temperature 37º C or at cold temperature 4º C
for an hour before the drug treatment. After an hour, cells were exposed to coumarin-6
(green fluorescent dye) labeled PLGA-ORM nanoparticles at 10, 20 and 25 µM
concentrations for an additional hour. Next, cells were washed twice with PBS, trypsized,
centrifuged, collected in PBS and analyzed with Accuri BD C6 flow cytometer in FL1
channel.
Cellular Uptake Mechanism
For this analysis, both cell lines Caski and SiHa were seeded at 2x105/well in a 6well format plate and allowed to attach overnight. Next morning, cells were pretreated
with different endocytosis pathway inhibitors such as Genistein (caveola mediated
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endocytosis at 200 µM), Amiloride (micropinocytosis endocytosis at 10 mM), Nocodazol
(microtubule mediated endocytosis at 20 µM), Chloropromazen (clathrin mediated
endocytosis at 10 µg/mL) and Methyle-β-cyclodextrin (lipid rafts mediated endocytosis
at 10 mM) for 1 hour. Thereafter, cells were exposed to coumarin-6 (green fluorescent
dye) labeled PLGA-ORM nanoparticles for the next hour at 37º C. After an hour, cells
were washed twice with PBS, trypsinized, centrifuged, collected in PBS and analyzed
with Accuri BC C6 flow cytometer in FL1 channel.
Cell Proliferation
Both Caski and SiHa (5000 cells/well) cell lines were seeded in 96 well plates and
allowed to attach overnight. Following day, cells were treated with different micromolar
concentrations (ranging from 10, 20 and 30 µM of free ORM and PLGA-ORM and were
incubated for 48 hour time course. Assay was performed by utilizing an MTS CellTiter96
Aqueous One Solution. At the end of the indicated time point, 20 µL MTS reagent was
added to each well and incubated at 37º C for next 2-4 hours. The absorbency was
measured at 490 nm by using microplate spectra photometer. Experiment was done in
duplicates and repeated three individual times. Data was compared to vehicle controls.
Colony Formation Assay
Caski and SiHa cells were seeded at 500/well in 6 well plates and allowed to
adhere overnight. Following day, cells were treated with 2.5, 5, 10 µM of free ORM and
PLGA-ORM and their respective vehicle controls and maintained for another 12-14 days.
On the 14th day cells were washed with PBS, fixed with ice cold methanol, stained with
hematoxylin (Thermo Fisher), and washed with water. Colonies that were visible (~50
cells) were counted manually and compared to the vehicle control ETOH and PLGA
control to obtain the final result. Experiment was done in duplicate and repeated three
individual times.
Real Time Cell Proliferation Kinetic Assay Using xCELLigence System
The xCELLigence system was used in order to evaluate the effects of PLGAORM on real time cellular proliferation/growth kinetics. xCELLigence system is an
electrical impedance-based method that provides the real time proliferation
measurements. For this experiment we used E plate VIEW 16 (ACEA Biosciences)
which were pre-incubated with 30 µL media for 30 min at 37º C and for the background
measurement. After 30 min, Caski and SiHa cells were plated at 8×103/chamber in 100
µL media with drug treatments (20 µM ormeloxifene and PLGA-ORM) in it. Plates were
incubated in xCELLigence instrument chamber at 37° C with 5% CO2 for real time cell
proliferation analysis. Experiment was done twice.
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Mitochondrial Membrane Potential by TMRE
Both Caski and SiHa cells were plated at 200,000/well in 6 well plates and
allowed to attach overnight. Next day cells were exposed to ORM and PLGA-ORM at 25
µM concentration along with their vehicle controls. At the indicated time point, cells
were trypsinized, washed, centrifuged and the final pellet was resuspended in 1 mL PBS
containing 50 nM TMRE stain. Cells were incubated with TMRE for 30 minutes in the
dark at room temperature. After the incubation is completed, cells were analyzed by BD
Accuri C6 flow cytometer under FL2 channel. The experiment was performed three
times.
Statistical Analysis
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software.
Results
PLGA-ORM Nanoparticles Internalize in Cervical Cancer Cells
Measuring in vitro cellular internalization of nanoparticle is an essential
experiment. We used fluorescent microscope and flow cytometer for measuring the
cellular uptake of PLGA-ORM nanoparticles in cervical cancer calls. The microscopic
images and flow cytometer data revealed that particles were being taken up by Caski
(Figure 8-1 and Figure 8-2) and SiHa (Figure 8-3 and Figure 8-4) cell lines in time and
dose dependent manners. These images suggested that PLGA-ORM was primarily
located at the cytoplasm of these cells. TEM images data (Figure 8-5, Figure 8-6,
Figure 8-7 and Figure 8-8) was also consistent with this finding. TEM images revealed
that PLGA-ORM was internalized in cells just with 3 hours of treatment while no uptake
was seen in free ORM treated samples. Temperature is an important factor that facilitates
the uptake of particles. In some cases, particle uptake is energy/temperature dependent.
Thus, we conducted a flow cytometry study with two different temperatures. The results
from this experiment showed that at 4º C temperature particle uptake was blocked
whereas at 37º C, the physiological temperature, the uptake of particles was normal
(Figure 8-9 and Figure 8-10).
PLGA-ORM Nanoparticles Utilizes Endocytosis Pathway for Internalization in
Cervical Cancer Cells
Endocytosis is the main pathway that nanoparticles use for internalizing into the
cells. But endocytosis has various different mechanisms/pathways for cellular uptake
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Figure 8-1. Qualitative representation of cellular uptake of coumarin-6 loaded
PLGA-ORM nanoparticles in Caski cells.

Figure 8-2. Coumarin-6 loaded PLGA-ORM internalization in Caski cells.
Cells showed an increasing uptake pattern of particles in dose and time dependent
manner. Results were normalized to the PLGA control particles. Error bars show SEM,
n=3. *p<0.05.
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Figure 8-3.
Qualitative representation of cellular uptake of coumarin-6 loaded
PLGA-ORM nanoparticles in SiHa cells.
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Figure 8-4. Coumarin-6 loaded PLGA-ORM internalization in SiHa cells.
Cells showed an increasing uptake pattern of particles in dose and time dependent
manner. Results were normalized to the PLGA control particles. Error bars show SEM,
n=3. *p<0.05.
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Figure 8-5.

Cellular internalization of free ORM in Caski cells showed by TEM.

95

Figure 8-6.
TEM.

Cellular internalization of PLGA-ORM in Caski cells showed by
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Figure 8-7.

Cellular internalization of free ORM in SiHa cells showed by TEM.
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Figure 8-8.

Cellular internalization of PLGA-ORM in SiHa cells showed by TEM.
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Figure 8-9. Internalization of Coumarin-6 loaded PLGA-ORM is energy
dependent in Caski cells.
Cells showed blocked or inhibited uptake of particles when incubated at 4º C
temperature. Results were normalized to the PLGA control particles. Error bars show
SEM, n=3. *p<0.05.
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Figure 8-10. Internalization of Coumarin-6 loaded PLGA-ORM is energy
dependent in SiHa cells.
Cells showed blocked or inhibited uptake of particles when incubated at 4º C
temperature. Results were normalized to the PLGA control particles. Error bars show
SEM, n=3. *p<0.05.
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(Figure 8-11) [197]. Therefore to determine the uptake mechanism of PLGA-ORM
nanoparticles, we treated Caski and SiHa cells with different endocytosis pathway
inhibitors and performed flow cytometery. Data from this experiment suggested that
particles mainly utilized the lipid raft, caveolae and micropinocytosis pathways to get
into the Caski cells (Figure 8-12). While in SiHa cells particles preferred lipid raft,
clatherin, caveolae and micropinocytosis pathways for their internalization (Figure 8-13).
PLGA-ORM Decreases Cellular Viability, Clonogenic Potential and Mitochondrial
Membrane Potential of Cervical Cancer Cells
In order to elaborate anti-cancerous properties of PLGA-ORM, we assessed an
MTS assay for 48 hours. The results showed a marked decrease in cellular viability of
both cell lines (Figure 8-14 and Figure 8-15) when compared to free ORM. When we
performed the colony formation assay for the long term treatment capability of PLGAORM, the results were even better. PLGA-ORM had an inhibitory effect on clonogenic
potential of both Caski and SiHa cells in comparison to free ORM (Figure 8-16, Figure
8-17, Figure 8-18 and Figure 8-19). Interestingly, PLGA-ORM had lower number of
colonies than free ORM even at the lowest concentration of 2.5 µM. Real time growth
kinetics by the xCELLigence system also supported these findings (Figure 8-20 and
Figure 8-21). We also performed a Flow cytometry experiment to analyze the ability of
PLGA-ORM to induce apoptosis. We used TMRE stain to detect the depolarized
mitochondria which is an indication of apoptosis induction. Our flow cytometer data
revealed that PLGA-ORM significantly reduced the mitochondrial membrane potential of
both Caski and SiHa cells when compared to free ORM (Figure 8-22 and Figure 8-23).
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Figure 8-11. Representation of different endocytosis pathway and their inhibitors.
Modified with permission. Mayor, S. and R.E. Pagano, Pathways of clathrin-independent
endocytosis. Nature reviews Molecular cell biology, 2007. 8(8): p. 603-612.
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Figure 8-12. PLGA-ORM nanoparticles entered Caski cells using endocytosis
pathway.
Cellular uptake of formulation after using different endocytosis pathway inhibitors.
Results were normalized to the PLGA-ORM C6 particles. Error bars show SEM, n=3.
*p<0.05.
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Figure 8-13. PLGA-ORM nanoparticles entered SiHa cells using endocytosis
pathway.
Cellular uptake of formulation after using different endocytosis pathway inhibitors.
Results were normalized to the PLGA-ORM C6 particles. Error bars show SEM, n=3.
*p<0.05.

104

Figure 8-14. PLGA-ORM decreased cellular proliferation of Caski cells.
Cells were treated with ormeloxifene and PLGA-ORM (10, 20 and 30 µM) for 48 hrs,
MTS method was used to determine proliferation, and absorbance was measured at 490
nm. Results were normalized to the vehicle controls (ETOH and PLGA) and free
ormeloxifene. Error bars show SEM, n=3. *p<0.05.
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Figure 8-15. PLGA-ORM decreased cellular proliferation of SiHa cells.
Cells were treated with ormeloxifene and PLGA-ORM (10, 20 and 30 µM) for 48 hrs,
MTS method was used to determine proliferation, and absorbance was measured at 490
nm. Results were normalized to the vehicle controls (ETOH and PLGA) and free
ormeloxifene. Error bars show SEM, n=3. *p<0.05.

Figure 8-16. PLGA-ORM decreased colony forming ability of Caski cells.
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days.
Images were taken at 200X using a phase contrast microscope.
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Figure 8-17. Bar graph showing that PLGA-ORM decreased colony forming
ability of Caski cells.
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days.
Results were normalized to the vehicle controls (ETOH and PLGA) and free
ormeloxifene. Error bars show SEM, n=3. *p<0.05.

Figure 8-18. PLGA-ORM decreased colony forming ability of SiHa cells.
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days.
Images were taken at 200X using a phase contrast microscope.
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Figure 8-19. Bar graph showing that PLGA-ORM decreased colony forming
ability of SiHa cells.
Cells were treated with ormeloxifene and PLGA-ORM (2.5, 5 and 10 µM) for 14 days.
Results were normalized to the vehicle controls (ETOH and PLGA) and free
ormeloxifene. Error bars show SEM, n=3. *p<0.05.
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Figure 8-20. PLGA-ORM inhibited growth of Caski cells in real time.
Cells were exposed to ormeloxifene and PLGA-ORM treatments and then measured for
real time growth kinetics.

Figure 8-21. PLGA-ORM inhibited growth of SiHa cells in real time.
Cells were exposed to ormeloxifene and PLGA-ORM treatments and then measured for
real time growth kinetics.
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Figure 8-22. PLGA-ORM reduced mitochondrial membrane potential of Caski
cells as measured by TMRE stain using flow cytometer.
Cells were treated with ormeloxifene and PLGA-ORM for 24 hours. Results were
normalized to the vehicle controls (ETOH and PLGA) and free ormeloxifene. Error bars
show SEM, n=3. *p<0.05.
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Figure 8-23. PLGA-ORM reduced mitochondrial membrane potential of SiHa cells
as measured by TMRE stain using flow cytometer.
Cells were treated with ormeloxifene and PLGA-ORM for 24 hours. Results were
normalized to the vehicle controls (ETOH and PLGA) and free ormeloxifene. Error bars
show SEM, n=3. *p<0.05.
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CHAPTER 9. IN VIVO VALIDATION OF ANTI-CANCEROUS/TUMOROUS
FUNCTION OF ORMELOXIFENE AND PLGA-ORM
Materials and Methods
In vivo Orthotopic Tumoral Study
In order to study the anti-tumoral properties of ormeloxifene and PLGA-ORM,
we developed an orthotopic mice model for cervical cancer (Figure 9-1). 4-6 weeks-old
nu/nu female mice were purchased from Jackson laboratories and maintained in a
pathogen-free environment. HPV positive Caski cervical cancer cells (5X106 per mouse)
were suspended in PBS and matrigel (BD Bioscience) at a 1:1 ratio. Cell suspension
(5X106 cells in 100 µL) was injected orthotopically direct to the cervix of each mouse.
Mice were monitored for the tumor development and once tumor reached the size of
around 100 mm3, we started the drug treatment. Mice were treated with free ORM,
PLGA-ORM, PBS and PLGA NPs (vehicle controls) at the concentration of 100
µg/mouse (chosen based upon our previous studies in the lab) intraperitoneally (i.p.) for
the systemic therapy. Tumor volumes were measured by using a digital vernier caliper
and calculated using the formula of tumor volume (mm3) = π/6 x L x W x H measured bidimensionally, and survival was noted up to day 40. Mice survival was analyzed by
Kaplan Meir analysis. Mice were sacrificed during the experiment if tumor
volume/weight reached more than 10% of body weight (1.5-2.0 gram) or if mice lost
more than 10% of their total body weight. On day 40, mice were euthanized and tumors
were observed and dissected.
Statistical Analysis
Statistical analysis was determined by using an unpaired, two tailed student’s ttest. The results were considered significant if P< 0.05. All graphs were generated using
GraphPad Prism5 software.
Results
PLGA-ORM nanoparticles inhibited cervical cancer tumorigenesis in orthotopic
mice model. It is imperative to test PLGA-ORM in vivo after seeing its anti-cancerous
prosperities in in vitro system. In order to evaluate anti-tumorous efficacy of PLGAORM, we generated an orthotopic cervical cancer mouse model using female nude mice.
For this mouse model development, we used HPV positive Caski cervical cancer cells
and injected directly into the cervix of these female nude mice. Mice started developing
tumors within 15-20 days. Once the tumor size was around 100 mm3, free ORM and
PLGA-ORM along with their respective controls PBS and PLGA were administered by
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Figure 9-1.

Schematic of in vivo study.
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intra-peritoneal injections (Figure 9-1). The study was terminated when the tumor size
reached around 1000 mm3, at the termination, mice were euthanized and tumors were
dissected from all groups (Figure 9-2). During the entire study tumor size/volume was
measured. ORM and PLGA-ORM significantly decreased the tumor volume when
compared to their respective controls (Figure 9.3). We also measured the tumor weight
after dissection and results suggested that ORM and PLGA-ORM reduced the tumor
weight markedly when compared to their controls (Figure 9-4). Interestingly, PLGAORM had more inhibitory effect on tumor size and weight than that observed with free
ORM (Figure 9-3 and Figure 9-4). After further validation, it was observed that ORM
and PLGA-ORM also increased the overall mice survival rate (Figure 9-5).

Figure 9-2. Images represent mice from different treatment groups and their
dissected tumors

114

Figure 9-3. PLGA-ORM inhibited tumor growth of cervical cancer orthotopic
mice model.
Average tumor volume of ormeloxifene and PLGA-ORM treated mice. Error bars show
SEM, n=6.
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Figure 9-4. Weight measurement from the tumors dissected from mice.
ORM and PLGA-ORM significantly reduced the tumor weight when compared to their
respective vehicle controls PBS and PLGA, Error bars show SEM, n=6. *p<0.05.
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Figure 9-5. Percent survival curve for ORM and PLGA-ORM treated mice.
PLGA-ORM (Red Line) showed the 100% survival over other groups.
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CHAPTER 10.

DISCUSSION*

Despite of having various preventative modalities including vaccines and
screening, advanced stage cervical cancer is a deadly malignancy in women. Advanced
stages of cervical cancer remain untreatable as a result of many modulations at the
cellular and molecular level. Cells become more motile/ invasive and show resistance
towards chemo and radiotherapy. Thus, newer therapeutic modalities are highly desirable
that may provide protection against metastasis and chemo/radio-resistance. In the modern
research world, repurposing of already in use molecules has become a new attraction.
Considering the potential of repurposing a drug that is in use already, we investigated the
therapeutic potential of ormeloxifene in this study. Ormeloxifene has been used for its
birth control purposes for more than last two decades in India. Ormeloxifene targets high
proliferative decidual cells in the endometrium and it is reported safe to use. Recently,
studies from other groups as well as our lab have demonstrated that ormeloxifene has
anti-cancerous activities against breast, head and neck, ovarian, pancreatic and leukemia
cancers.
Uncontrolled cell proliferation/ growth and inability to have programmed cell
death are the major causes of cancer development. In this study we show that
ormeloxifene decreases cellular proliferation of four different cells, both HPV positive
and negative with a short term (48 hrs) treatment of ormeloxifene at micro-molar
concentrations confirmed by MTS assay. Results from xCELLigence real time growth
kinetic assay are also consistent with MTS data findings. Ormeloxifene also inhibits the
clonogenic potential of all four cell lines with a long term treatment of about 14/15 days.
Results are consistent with previous work on ormeloxifene’s anti-proliferative potential.
Upon the drug treatment, cells exhibit clear signs of apoptosis. Ormeloxifene treatment
alters the morphology of Caski and SiHa cells and shows the apoptosis like signs such as
membrane blebbing, cell shrinkage and round of shape. Apoptosis is a major event that
occurs in response to many anti-cancer drugs. Apoptosis consists of two different
pathways, namely extrinsic and intrinsic. Intrinsic apoptotic death cascade involves the
depolarization of mitochondrial membrane as a first event of the cascade that further
leads to activation of Caspase and results in PARP cleavage. Ormeloxifene treatment for
24 hours affects the mitochondrial membrane depolarization as confirmed by decreased
mitochondrial membrane potential assessed by TMRE staining through fluorescent
microscopy and flow cytometer. Annexin V-7AAD staining is another method to detect
the apoptotic cell population. Ormeloxifene treatment for 24 hours results in increased
apoptotic population of Caski and SiHa cells which indicates that ormeloxifene has a
potential to become anti-proliferative/growth molecule for cervical cancer.
Excessive cell cycle progression is a key property of cancerous cells and
controlled by many activated cyclins and their dependent kinase. Ormeloxifene treatment
----------------------------* Adapted with permission. Khan, S., et al., Nanoparticle formulation of ormeloxifene for
pancreatic cancer. Biomaterials, 2015. 53: p. 731-743.
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plays an inhibitory role in cell cycle progression of Caski and SiHa cells. It arrests cell
cycle in both cell lines at G1-S transition and decreases the expression of Cyclin E and its
dependent kinase CDk2. Cyclin E and cdk2 help cells to progress from G1 phase to S
phase. PI3K-Akt pathways play an important role in cell growth and cell cycle
progression. In accordance with previous findings, we show that ormeloxifene
downregulates the PI3K-Akt pathway in cervical cancer cells as shown by decreased
expression levels of PI3K and Akt, and increased phosphorylation of Akt. Ormeloxifene
further decreases the downstream target of PI3K-Akt pathway, p21, a known inhibitor of
cell cycle progression. Cancer cells show enhanced motility and invasion which helps
cancer cells migrate from one organ to another and this is how cancer spreads. Molecules
that inhibit migratory and invasive property of cancer cells are the strong candidates for
having anti-cancerous properties. We utilized various techniques including agarose bead
assay, Boyden chamber migration, invasion assay and real time migration/invasion by
xCELLigence to confirm ormeloxifene’s effect on motility of Caski and SiHa cell lines.
Results reveal that cells become less motile and invasive with ormeloxifene treatment for
24 hours.
Persistent HPV infection is required for the progression of cervical cancer so we
intended to assess ormeloxifene’s effect on HPV E6 and E7 expression. Ormeloxifene
successfully inhibits the mRNA levels of HPV E6 and E7 with 6 hours of treatment; the
downregulation also continued to the translational levels as ormeloxifene decreases the
expression of HPV E6 and E7 oncoproteins with 24 hours treatment. HPV E6 and E7
deregulate the cell cycle by inactivating tumor suppressor proteins p53, Rb and PTPN13;
interestingly, ormeloxifene unregulated the expression of these three proteins. These
findings suggest that ormeloxifene not only decreases the oncogenic signaling but also
increases the tumor suppressing signaling, thus, demonstrates potent anti-HPV properties
in cervical cancer cells.
Ormeloxifene also sensitized Caski cervical cancer cells to radiation. Data
showed that pre-treatment of ormeloxifene (24 hours prior to radiation exposure for
proliferation and 6 hours prior for colony formation) had better and improved growth
inhibitory effects on cells when compared with ormeloxifene and radiation alone.
Ormeloxifene is a synthetic molecule which is widely used as an oral
contraceptive in humans and exhibits potent anti-cancer activity by targeting the key
underlying oncogenic molecular mechanisms [198-205]. Hence, our aim of this study
was to enhance ORM delivery at the tumor site for improved therapeutic effects/index for
cervical cancer treatment. To this end, we have developed an efficient PLGA NP (PLGAORM NP) based delivery system, to enhance the anti-cancer efficiency of ORM at the
tumor site. In the present study, an optimized PLGA-ORM 20 NP formulation was made
with an average particle size of 101.4 ± 1.5 nm with 84.96 ± 4.75% drug-loading
capacity. This formulation provides good suspension while maintaining long-term
stability, up to 6 months. From the results of FT-IR, DSC, and TGA, it is evident that
PLGA, PVA, and PLL polymers form undefined structure in PLGA-ORM NPs, which
allow for the controlled release in cancer cells. We observed that PLGA-ORM NPs
delivered a higher payload of ORM in cervical cancer cells which was correlated with the

119

increased cytotoxicity in cervical cancer cells. Elucidating the internalization mechanisms
could provide crucial insights into engineering novel cancer therapeutics yielding more
potent and selective nanoformulations. The uptake and internalization of PLGA-ORM
NPs follow an endocytotic pathway, which is consistent with most of the conventional
nanoformulations [206].
This study with PLGA-ORM NPs demonstrates enhanced anti-cancer effects over
free ORM against four different cervical cancer cell lines in proliferation and clonogenic
potential assays. Additionally, PLGA-ORM induces apoptosis in cervical cancer cells.
From a clinical translational point of view, achieving the highest drug loading is more
favorable for clinical use to improve pharmacokinetic profiles. Therefore, we have
engineered an optimized PLGA-ORM20 NP formulation with higher loading capacity.
The higher drug loading not only minimizes (i) processing, (ii) overall raw materials, and
(iii) non-active ingredients for generating the formulation, but efficiently delivers an
equivalent dose of ORM. Overall, in this proof-of-concept study, we have demonstrated
that PLGA-ORM20 NP formulation is highly suitable to deliver ORM more efficiently at
the tumor site to induce superior anti-cancer activity.
After discussing all the outcomes of this work, it can be said that the central
hypothesis and the questions asked, were completely justified in this dissertation work.
This dissertation work provides an insight on an upcoming repurposed molecule that has
great potential to become an anti-cervical cancer agent. This work holds substantial
promises for future, thus, needs to be continued in order to further understand the
underlying mechanisms of these results. Our data indicated that PI3K-Akt which is one of
the main stream pathways involved in cervical cancer carcinogenesis is inhibited by
ormeloxifene so further work is required to establish this pathway as the mechanism of
action for ormeloxifene in cervical cancer. Our combination therapy data with
ormeloxifene and radiation on proliferation/growth studies also exhibited excellent
outcomes. This work certainly needs to be carried forward in future where it can be tested
in vitro and in vivo to investigate a combination therapy for cervical cancer management.
Also, the in vitro and in vivo studies with nanoformulation of ormeloxifene revealed its
future commercial prospective. Summing up, this dissertation work holds a considerable
potential to be extended in future and to be continued in translational settings.
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